^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OvaCis®

    Company:
    INEX Innovate
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    OvaCis® is a globally patented Point-Of-Care device that accurately discriminates benign from malignant epithelial Ovarian Cancer in 15 minutes. OvaCis® is based on patented technology that works by detecting homogeneous biomarker in ovarian cyst fluid. The reagents in the device combine to yield a colorimetric reaction which displays if the cancer is malignant (positive) or benign (negative). Device used intra-operative and results in 15 minutes.
    Cancer:
    Ovarian Cancer
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    05/11/22
    OC
    -
    FDA